Merck bulks up in haematology, buying Imago for $1.35bn While its fabled takeover of Seagen is yet to materialise, Merck & Co has continued to bolster its pipeline with smaller deals – with its latest ...
MSD has kicked off a new phase 3 trial of its oral LSD1 inhibitor bomedemstat in essential thrombocythaemia (ET), one of a rare type of blood cancer known as myeloproliferative neoplasms (MPNs). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results